Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Med Chem ; 65(3): 2149-2173, 2022 02 10.
Artículo en Inglés | MEDLINE | ID: mdl-35080396

RESUMEN

Pseudomonas aeruginosa is of major concern for cystic fibrosis patients where this infection can be fatal. With the emergence of drug-resistant strains, there is an urgent need to develop novel antibiotics against P. aeruginosa. MurB is a promising target for novel antibiotic development as it is involved in the cell wall biosynthesis. MurB has been shown to be essential in P. aeruginosa, and importantly, no MurB homologue exists in eukaryotic cells. A fragment-based drug discovery approach was used to target Pa MurB. This led to the identification of a number of fragments, which were shown to bind to MurB. One fragment, a phenylpyrazole scaffold, was shown by ITC to bind with an affinity of Kd = 2.88 mM (LE 0.23). Using a structure guided approach, different substitutions were synthesized and the initial fragment was optimized to obtain a small molecule with Kd = 3.57 µM (LE 0.35).


Asunto(s)
Antibacterianos/química , Proteínas Bacterianas/antagonistas & inhibidores , Oxidorreductasas/antagonistas & inhibidores , Pseudomonas aeruginosa/enzimología , Antibacterianos/metabolismo , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Proteínas Bacterianas/metabolismo , Sitios de Unión , Dominio Catalítico , Cristalografía por Rayos X , Fibrosis Quística/complicaciones , Fibrosis Quística/mortalidad , Fibrosis Quística/patología , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Conformación Molecular , Simulación del Acoplamiento Molecular , Oxidorreductasas/metabolismo , Infecciones por Pseudomonas/complicaciones , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Pirazoles/química , Pirazoles/metabolismo , Pirazoles/farmacología , Pirazoles/uso terapéutico
2.
Sci Rep ; 6: 23349, 2016 Mar 22.
Artículo en Inglés | MEDLINE | ID: mdl-27000658

RESUMEN

More than 46 million people worldwide suffer from Alzheimer's disease. A large number of potential treatments have been proposed; among these, the inhibition of the aggregation of amyloid ß-peptide (Aß), considered one of the main culprits in Alzheimer's disease. Limitations in monitoring the aggregation of Aß in cells and tissues restrict the screening of anti-amyloid drugs to in vitro studies in most cases. We have developed a simple but powerful method to track Aß aggregation in vivo in real-time, using bacteria as in vivo amyloid reservoir. We use the specific amyloid dye Thioflavin-S (Th-S) to stain bacterial inclusion bodies (IBs), in this case mainly formed of Aß in amyloid conformation. Th-S binding to amyloids leads to an increment of fluorescence that can be monitored. The quantification of the Th-S fluorescence along the time allows tracking Aß aggregation and the effect of potential anti-aggregating agents.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Péptidos beta-Amiloides/antagonistas & inhibidores , Secuencia de Aminoácidos , Péptidos beta-Amiloides/química , Evaluación Preclínica de Medicamentos , Fluorescencia , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA